T1	SectionAnnotate 227 253	History of Present Illness
T2	SectionAnnotate 1359 1428	present review of systems was reviewed and notable for the following:
T3	SectionAnnotate 1886 1907	Past Medical History:
T4	SectionAnnotate 2302 2317	FAMILY HISTORY:
T5	SectionAnnotate 2319 2333	Family History
T6	SectionAnnotate 2487 2514	PERSONAL AND SOCIAL HISTORY
T7	SectionSkip 2999 4045	Physical Exam:  ECOG PS 0  Blood pressure (!) 172/103, pulse 83, temperature 36.4 C (97.6 F), temperature source Temporal, resp. rate 16, height 172.5 cm (5' 7.91"), weight 82.1 kg (181 lb), SpO2 97 %.  General appearance: No acute distress, conversant, appropriately interactive. Non-toxic, well-appearing.   Eyes: anicteric sclerae, moist conjunctivae; no lid lag.   HEENT: Atraumatic; oropharynx clear with moist mucous membranes and no mucosal ulcerations; normal hard and soft palate  Neck: Full range of motion, supple, no lymphadenopathy  Lungs/respiratory: Clear to auscultation, with normal respiratory effort and no intercostal retractions  Cardiovascular: RRR, normal S1 S2, no murmurs, gallops, or rubs.  Abdomen/GI: Soft, non-tender, nondistended; no masses, ascites, or hepatomegaly. Tympanitic to percussion.  Back: No point spinal tenderness.  Extremities: No peripheral edema or discoloration 
 palpated or visualized.  Skin: Normal temperature, turgor and texture; no rash, ulcers or subcutaneous nodules visualized or palpated.
T8	SectionSkip 4218 4619	Relevant Diagnostic Studies:    Most recent labs notable for the following:    03/25/2021  WBC 6.0, Hct 46.5, plts 207  Creat 1.16  Alb 4.3, AST/ALT 26/61, tot bili 0.6, alk phos 63      I personally reviewed and interpreted the patient's relevant imaging studies in conjunction with the corresponding formal radiology reports, as follows:    CT Abdomen /Pelvis with Contrast   Result Date: 05/21/2021
T9	SectionSkip 4621 6392	FINDINGS:    Lines / tubes: None.     Lower Thorax: Normal.      Hepatobiliary:    Liver: Measures 14.9 cm in craniocaudal dimension. Multiple varying sized hypodense lesions   throughout the right and left lobes of the liver are present measuring up to 1.7 x 1.4 cm in   segment March 13 (axial image 19, series 2) and 0.9 x 0.8 cm in segments August 15 (axial image 16,   series 2).    Gallbladder: Normal.    Bile Ducts: Normal.    Hepatic vasculature: Normal.     Spleen: A wedge-shaped hypodense area is noted in the lower part of the spleen most likely   related to an infarct. Spleen is upper limits of normal size measuring 12.6 cm.     Pancreas: A 5 x 4.1 cm cystic lesion with irregular rim enhancement is noted involving the   pancreatic tail and abutting the splenic hilum. No pancreatic duct dilatation is noted.     Adrenals: Normal.     Kidneys/Ureters: Normal.     GI Tract:    GE junction and stomach: Normal.    Small bowel: Normal in diameter    Appendix: Not visualized.    Colon and rectum: Diffuse wall thickening of the descending and sigmoid colon is present.     Peritoneum / Retroperitoneum: Nodular foci of enhancement involving the greater omentum is   present. Small peritoneal free fluid is 
 present. Irregular foci of nodular peritoneal   enhancement are present. Example in the left lateral peritoneal line (axial image 42, series   2).     Diffuse mesenteric edema with interspersed fluid is noted.     Lymph Nodes: Multiple retroperitoneal lymph nodes are present in an example left periaortic   lymph node (axial image 42, series 2) measuring 0.9 x 1.1 cm.     Vessels: Moderate atherosclerotic ossification of aorta.     Pelvis:    Prostate: Normal.    Seminal vesicles: Normal.    Bladder: Normal.     Bones and Soft Tissues: Normal.
T10	SectionAnnotate 6397 6408	IMPRESSION:
T11	SectionAnnotate 7135 7166	Impression and Recommendations:
T12	PROBLEM 331 372	intermittent mid/LUQ abdominal discomfort
T13	PROBLEM 374 382	bloating
T14	PROBLEM 388 397	gassiness
T15	PROBLEM 478 492	These symptoms
T16	TEST 539 555	diagnostic tests
T17	TEST 601 604	EGD
T18	TEST 612 623	colonoscopy
T19	PROBLEM 629 671	2 tubular adenomas in the rectum and cecum
T20	TEST 687 700	Stool studies
T21	PROBLEM 714 734	infectious organisms
T22	TREATMENT 762 775	metronidazole
T23	TREATMENT 780 789	rifaximin
T24	TREATMENT 802 812	probiotics
T25	TREATMENT 819 840	dietary modifications
T26	TEST 872 885	Abdominal U/S
T27	PROBLEM 898 925	prominent hepatic steatosis
T28	PROBLEM 930 942	splenomegaly
T29	TEST 958 982	Abdominal/pelvic CT scan
T30	PROBLEM 984 1013	pancreatic tail cystic lesion
T31	PROBLEM 1026 1050	multiple hepatic lesions
T32	PROBLEM 1066 1076	metastases
T33	PROBLEM 1103 1128	peritoneal carcinomatosis
T34	TEST 1170 1173	EUS
T35	PROBLEM 1196 1216	pancreatic tail mass
T36	PROBLEM 1243 1273	cystic and necrotic components
T37	PROBLEM 1275 1308	fine needle bx c/w adenocarcinoma
T38	PROBLEM 1310 1322	MMR proteins
T39	PROBLEM 1447 1465	some early satiety
T40	PROBLEM 1470 1493	postprandial distention
T41	PROBLEM 1494 1504	discomfort
T42	PROBLEM 1506 1522	8 lb weight loss
T43	MedicationName 1541 1548	Tylenol
T44	PROBLEM 1553 1573	abdominal discomfort
T45	TREATMENT 1582 1590	Percocet
T46	PROBLEM 1594 1610	Semi-regular BMs
T47	PROBLEM 1615 1623	bleeding
T48	PROBLEM 1627 1647	Normally very active
T49	PROBLEM 1681 1687	fevers
T50	PROBLEM 1688 1694	chills
T51	PROBLEM 1695 1707	night sweats
T52	PROBLEM 1714 1756	pre-existing peripheral sensory neuropathy
T53	PROBLEM 1763 1766	SOB
T54	PROBLEM 1768 1773	cough
T55	PROBLEM 1778 1798	respiratory symptoms
T56	PROBLEM 1806 1818	jaundice sxs
T57	PROBLEM 1826 1840	modest anxiety
T58	PROBLEM 1929 1936	Anxiety
T59	PROBLEM 1959 1989	Environmental allergies    HIV
T60	TREATMENT 2003 2014	Medications
T61	TREATMENT 2019 2053	oxyCODONE-acetaminophen (Percocet)
T62	PROBLEM 2128 2139	severe pain
T63	TREATMENT 2175 2197	valACYclovir (Valtrex)
T64	PROBLEM 2216 2226	cold sores
T65	TREATMENT 2230 2239	Lorazepam
T66	PROBLEM 2249 2258	Allergies
T67	PROBLEM 2281 2296	Known Allergies
T68	ClinicalCondition 2375 2389	Ovarian cancer
T69	ClinicalCondition 2403 2414	Lung cancer
T70	ClinicalCondition 2442 2455	Breast cancer
T71	TEST 3015 3022	ECOG PS
T72	TEST 3026 3040	Blood pressure
T73	TEST 3054 3059	pulse
T74	TEST 3064 3075	temperature
T75	TEST 3081 3082	C
T76	TEST 3093 3111	temperature source
T77	TEST 3122 3126	resp
T78	TEST 3128 3132	rate
T79	TEST 3137 3143	height
T80	TEST 3165 3171	weight
T81	TEST 3190 3194	SpO2
T82	PROBLEM 3225 3239	acute distress
T83	PROBLEM 3315 3332	anicteric sclerae
T84	PROBLEM 3357 3364	lid lag
T85	PROBLEM 3375 3385	Atraumatic
T86	PROBLEM 3439 3458	mucosal ulcerations
T87	PROBLEM 3528 3543	lymphadenopathy
T88	TEST 3573 3585	auscultation
T89	PROBLEM 3625 3648	intercostal retractions
T90	PROBLEM 3688 3695	murmurs
T91	PROBLEM 3697 3704	gallops
T92	PROBLEM 3709 3713	rubs
T93	PROBLEM 3734 3744	non-tender
T94	PROBLEM 3746 3758	nondistended
T95	PROBLEM 3763 3769	masses
T96	PROBLEM 3771 3778	ascites
T97	PROBLEM 3783 3795	hepatomegaly
T98	TEST 3811 3821	percussion
T99	PROBLEM 3833 3856	point spinal tenderness
T100	PROBLEM 3875 3891	peripheral edema
T101	PROBLEM 3895 3908	discoloration
T102	PROBLEM 3985 3989	rash
T103	PROBLEM 3991 3997	ulcers
T104	PROBLEM 4001 4021	subcutaneous nodules
T105	PROBLEM 4134 4161	focal sensorimotor deficits
T106	TEST 4309 4312	WBC
T107	TEST 4318 4321	Hct
T108	TEST 4328 4332	plts
T109	TEST 4338 4343	Creat
T110	TEST 4350 4353	Alb
T111	TEST 4359 4362	AST
T112	TEST 4363 4366	ALT
T113	TEST 4374 4382	tot bili
T114	TEST 4388 4396	alk phos
T115	TEST 4443 4481	the patient's relevant imaging studies
T116	TEST 4561 4593	CT Abdomen /Pelvis with Contrast
T117	PROBLEM 4755 4795	Multiple varying sized hypodense lesions
T118	TEST 4893 4906	segment March
T119	TEST 4911 4922	axial image
T120	TEST 4977 4988	axial image
T121	PROBLEM 5097 5126	A wedge-shaped hypodense area
T122	PROBLEM 5193 5203	an infarct
T123	PROBLEM 5276 5302	A 5 x 4.1 cm cystic lesion
T124	PROBLEM 5308 5333	irregular rim enhancement
T125	PROBLEM 5410 5436	pancreatic duct dilatation
T126	PROBLEM 5633 5692	Diffuse wall thickening of the descending and sigmoid colon
T127	PROBLEM 5739 5766	Nodular foci of enhancement
T128	PROBLEM 5811 5838	Small peritoneal free fluid
T129	PROBLEM 5853 5903	Irregular foci of nodular peritoneal   enhancement
T130	TEST 5962 5973	axial image
T131	PROBLEM 5995 6019	Diffuse mesenteric edema
T132	PROBLEM 6025 6043	interspersed fluid
T133	PROBLEM 6071 6107	Multiple retroperitoneal lymph nodes
T134	TEST 6164 6175	axial image
T135	PROBLEM 6227 6273	Moderate atherosclerotic ossification of aorta
T136	PROBLEM 6413 6438	A lobulated cystic lesion
T137	PROBLEM 6444 6459	rim enhancement
T138	PROBLEM 6550 6577	a cystic neoplastic process
T139	PROBLEM 6579 6608	necrotic   metastatic disease
T140	PROBLEM 6624 6642	prior inflammation
T141	PROBLEM 6649 6696	Multiple hypodense lesions throughout the liver
T142	PROBLEM 6726 6755	metastatic/neoplastic process
T143	PROBLEM 6762 6784	Diffuse omental caking
T144	PROBLEM 6806 6836	nodular peritoneal enhancement
T145	PROBLEM 6862 6887	peritoneal carcinomatosis
T146	PROBLEM 6889 6916	Small peritoneal free fluid
T147	PROBLEM 6921 6947	diffuse mesenteric   edema
T148	PROBLEM 6965 7016	Wall thickening of the descending and sigmoid colon
T149	PROBLEM 7024 7032	reactive
T150	PROBLEM 7036 7047	peritonitis
T151	PROBLEM 7064 7071	colitis
T152	PROBLEM 7078 7115	Prominent retroperitoneal lymph nodes
T153	PROBLEM 7213 7265	newly diagnosed metastatic pancreatic adenocarcinoma
T154	TEST 7351 7360	pathology
T155	TREATMENT 7455 7464	treatment
T156	TREATMENT 7483 7499	systemic therapy
T157	TREATMENT 7642 7651	treatment
T158	TREATMENT 7757 7764	therapy
T159	TREATMENT 7844 7866	care treatment options
T160	TREATMENT 7895 7916	chemotherapy regimens
T161	PROBLEM 7936 7964	metastatic pancreatic cancer
T162	TREATMENT 7985 7992	therapy
T163	PROBLEM 8045 8065	co-morbid conditions
T164	TREATMENT 8127 8158	FOLFIRINOX (biweekly infusional
T165	TREATMENT 8165 8175	leucovorin
T166	TREATMENT 8177 8187	irinotecan
T167	TREATMENT 8193 8204	oxaliplatin
T168	TREATMENT 8228 8239	gemcitabine
T169	TREATMENT 8245 8259	nab-paclitaxel
T170	TREATMENT 8377 8402	these respective regimens
T171	PROBLEM 8432 8438	nausea
T172	PROBLEM 8439 8447	vomiting
T173	Symptom 8449 8457	alopecia
T174	Symptom 8459 8466	fatigue
T175	Symptom 8468 8478	cytopenias
T176	Symptom 8484 8511	resultant immunosuppression
T177	Symptom 8519 8525	anemia
T178	Symptom 8531 8560	peripheral sensory neuropathy
T179	Symptom 8561 8577	cold sensitivity
T180	TREATMENT 8594 8607	SoC treatment
T181	TREATMENT 8632 8642	FOLFIRINOX
T182	TREATMENT 8727 8749	clinical trial options
T183	TREATMENT 8754 8778	the first-line treatment
T184	PROBLEM 8782 8810	metastatic pancreatic cancer
T185	TREATMENT 9037 9046	treatment
T186	TREATMENT 9060 9073	randomization
T187	TREATMENT 9084 9100	SOC chemotherapy
T188	TREATMENT 9102 9113	gemcitabine
T189	TREATMENT 9114 9128	nab-paclitaxel
T190	TREATMENT 9132 9142	FOLFIRINOX
T191	TREATMENT 9163 9188	experimental therapy arms
T192	TREATMENT 9244 9255	gemcitabine
T193	MedicationName 9256 9270	nab-paclitaxel
T194	MedicationName 9276 9287	pamrevlumab
T195	TREATMENT 9289 9334	an anti-CTGF (connective tissue growth factor
T196	TEST 9336 9355	monoclonal antibody
T197	PROBLEM 9386 9415	fresh tumor tissue collection
T198	TREATMENT 9520 9547	Cancer Immunotherapy (PICI)
T199	TREATMENT 9573 9590	a platform design
T200	TREATMENT 9603 9639	test multiple different chemotherapy
T201	TREATMENT 9640 9666	immunotherapy combinations
T202	TREATMENT 9753 9764	gemcitabine
T203	MedicationName 9765 9779	nab-paclitaxel
T204	MedicationName 9794 9812	hydroxychloroquine
T205	TREATMENT 9814 9837	an anti-autophagy agent
T206	TREATMENT 9856 9875	low-dose ipilimumab
T207	PROBLEM 9954 9977	archived tumor material
T208	TEST 9981 10009	a fresh pre-treatment biopsy
T209	TEST 10014 10034	correlative analyses
T210	TEST 10110 10131	somatic tumor testing
T211	TEST 10135 10163	the patient's tumor specimen
T212	PROBLEM 10229 10253	any actionable mutations
T213	PROBLEM 10257 10282	other genetic alterations
T214	TREATMENT 10306 10323	treatment options
T215	TREATMENT 10338 10361	already-approved agents
T216	TREATMENT 10595 10613	treatment purposes
T217	TEST 10657 10675	genetic counseling
T218	TEST 10681 10697	germline testing
T219	PROBLEM 10712 10751	any hereditary predisposition to cancer
T220	PROBLEM 10800 10819	a pancreatic cancer
T221	PROBLEM 10865 10883	known risk factors
T222	TREATMENT 11186 11216	several non-therapeutic trials
T223	TEST 11249 11262	novel imaging
T224	TEST 11267 11272	blood
T225	TEST 11278 11296	stool-based assays
T226	TEST 11302 11330	ctDNA and microbiome studies
T227	TEST 11669 11681	this 
 study
T228	PROBLEM 11724 11741	His active cancer
T229	PROBLEM 11753 11779	a life-threatening illness
T230	PROBLEM 11790 11803	complications
T231	TREATMENT 11828 11846	patient management
T232	TREATMENT 11854 11891	the patient's systemic cancer therapy
T233	TEST 11913 11933	intensive monitoring
T234	PROBLEM 11938 11981	potential major/life-threatening toxicities
T235	PROBLEM 12230 12247	His active cancer
T236	PROBLEM 12259 12285	a life-threatening illness
T237	PROBLEM 12296 12309	complications
T238	TREATMENT 12334 12352	patient management
T239	TREATMENT 12360 12397	the patient's systemic cancer therapy
T240	TEST 12419 12439	intensive monitoring
T241	PROBLEM 12444 12487	potential major/life-threatening toxicities
T242	Age 15 17	51
T243	Symptom 362 372	discomfort
A1	IsPresentOnFirstCancerDiagnosis T243 yes
A2	IsCausedByDiagnosedCancer T243 yes
A3	ChronicVal T243 non-chronic
A4	ContinuityVal T243 new
T244	Site 331 361	intermittent mid/LUQ abdominal
R1	SiteOf Arg1:T244 Arg2:T243	
T245	Symptom 374 382	bloating
A5	IsPresentOnFirstCancerDiagnosis T245 yes
A6	IsCausedByDiagnosedCancer T245 yes
A7	ChronicVal T245 non-chronic
A8	ContinuityVal T245 new
T246	Symptom 388 397	gassiness
A9	IsPresentOnFirstCancerDiagnosis T246 yes
A10	IsCausedByDiagnosedCancer T246 yes
A11	ChronicVal T246 non-chronic
A12	ContinuityVal T246 new
T247	Datetime 589 599	10/22/2020
T248	ProcedureName 601 604	EGD
A17	IntentVal T248 diagnosis
T249	ProcedureName 612 623	colonoscopy
A18	IntentVal T249 diagnosis
T250	ClinicalCondition 631 647	tubular adenomas
A19	IntentVal T250 screening
A20	ChronicVal T250 non-chronic
T251	Site 655 661	rectum
T252	Site 666 671	cecum
R2	SiteOf Arg1:T251 Arg2:T250	
R3	SiteOf Arg1:T252 Arg2:T250	
T253	Datetime 675 685	10/22/2020
R4	HappensAtOnDuring Arg1:T247 Arg2:T248	
T254	Datetime 738 751	December 2020
T255	MedicationName 762 775	metronidazole
A21	TreatmentContinuityVal T255 started
A22	TreatmentTypeVal T255 others
A23	TreatmentIntentVal T255 others
A24	TreatmentCategory T255 Others
T256	MedicationName 780 789	rifaximin
A25	TreatmentContinuityVal T256 started
A26	TreatmentTypeVal T256 others
A27	TreatmentIntentVal T256 others
A28	TreatmentCategory T256 Others
T257	MedicationName 802 812	probiotics
A29	TreatmentContinuityVal T257 started
A30	TreatmentTypeVal T257 others
A31	TreatmentIntentVal T257 others
A32	TreatmentCategory T257 Others
R6	BeginsOnOrAt Arg1:T254 Arg2:T255	
R7	BeginsOnOrAt Arg1:T254 Arg2:T256	
R8	HappensAfter Arg1:T254 Arg2:T257	
T258	Datetime 860 870	03/25/2021
T259	Radiology 872 885	Abdominal U/S
A33	IntentVal T259 diagnosis
T260	RadPathResult 898 925	prominent hepatic steatosis
A34	RadPathResultVal T260 Others
T261	RadPathResult 930 942	splenomegaly
A35	RadPathResultVal T261 Others
R9	ResultOfTest Desc:T260 Test:T259	
R10	ResultOfTest Desc:T261 Test:T259	
T262	Datetime 946 956	05/21/2021
T263	Radiology 958 982	Abdominal/pelvic CT scan
A36	IntentVal T263 diagnosis
T264	Radiology 1170 1173	EUS
A37	IntentVal T264 diagnosis
T265	RadPathResult 1000 1013	cystic lesion
A38	IntentVal T265 diagnosis
A39	RadPathResultVal T265 InitialCancerDiagnosis
T266	Site 984 999	pancreatic tail
R11	SiteOf Arg1:T266 Arg2:T265	
R12	ResultOfTest Desc:T265 Test:T263	
T267	Size 1015 1019	5 cm
A40	EpisodeDescription T267 FirstOccurrence
T268	Metastasis 1026 1050	multiple hepatic lesions
A41	EpisodeDescription T268 FirstOccurrence
T269	Metastasis 1103 1128	peritoneal carcinomatosis
A42	EpisodeDescription T269 FirstOccurrence
R13	TestOrProcedureReveals Test:T263 Desc:T268	
R14	TestOrProcedureReveals Test:T263 Desc:T269	
T270	RadPathResult 1212 1216	mass
A43	RadPathResultVal T270 InitialCancerDiagnosis
T271	Size 1218 1236	39.4 mm by 22.6 mm
A44	EpisodeDescription T271 FirstOccurrence
R15	ResultOfTest Desc:T270 Test:T264	
T272	ProcedureName 1275 1289	fine needle bx
A45	IntentVal T272 diagnosis
A46	IsTumorRemaining T272 yes
T273	Histology 1294 1308	adenocarcinoma
A47	EpisodeDescription T273 FirstOccurrence
R16	TestOrProcedureReveals Test:T272 Desc:T273	
R17	TestOrProcedureReveals Test:T264 Desc:T273	
T274	Symptom 1452 1465	early satiety
A48	IsPresentOnFirstCancerDiagnosis T274 yes
A49	IsCausedByDiagnosedCancer T274 yes
A50	ChronicVal T274 non-chronic
A51	ContinuityVal T274 stable
T275	Symptom 1470 1504	postprandial distention/discomfort
A52	IsPresentOnFirstCancerDiagnosis T275 yes
A53	IsCausedByDiagnosedCancer T275 yes
A54	ChronicVal T275 non-chronic
A55	ContinuityVal T275 stable
T276	Symptom 1506 1522	8 lb weight loss
A56	IsPresentOnFirstCancerDiagnosis T276 yes
A57	IsCausedByDiagnosedCancer T276 yes
A58	ChronicVal T276 non-chronic
A59	ContinuityVal T276 stable
T277	Symptom 1553 1573	abdominal discomfort
A60	IsPresentOnFirstCancerDiagnosis T277 yes
A61	IsCausedByDiagnosedCancer T277 yes
A62	ChronicVal T277 non-chronic
A63	ContinuityVal T277 stable
T278	Symptom 1615 1623	bleeding
A64	NegationModalityVal T278 negated
T279	Symptom 1681 1687	fevers
A65	NegationModalityVal T279 negated
T280	Symptom 1688 1694	chills
A66	NegationModalityVal T280 negated
T281	Symptom 1695 1707	night sweats
A67	NegationModalityVal T281 negated
T282	Symptom 1727 1756	peripheral sensory neuropathy
A68	NegationModalityVal T282 negated
T283	Symptom 1763 1766	SOB
A69	NegationModalityVal T283 negated
T284	Symptom 1768 1773	cough
A70	NegationModalityVal T284 negated
T285	Symptom 1778 1798	respiratory symptoms
A71	NegationModalityVal T285 negated
T286	Symptom 1806 1814	jaundice
A72	NegationModalityVal T286 negated
T287	Symptom 1833 1840	anxiety
A73	IsPresentOnFirstCancerDiagnosis T287 unclear
A74	IsCausedByDiagnosedCancer T287 unclear
A75	ContinuityVal T287 unclear
A76	TreatmentContinuityVal T43 continuing
A77	TreatmentTypeVal T43 others
A78	TreatmentIntentVal T43 others
A79	TreatmentCategory T43 Supportive
T288	MedicationName 1582 1590	Percocet
A80	TreatmentContinuityVal T288 continuing
A81	TreatmentTypeVal T288 others
A82	TreatmentIntentVal T288 others
A83	TreatmentCategory T288 Supportive
R18	TreatmentAdministeredForProblem Treatment:T43 Prob:T277	
R19	TreatmentAdministeredForProblem Treatment:T288 Prob:T277	
T289	Symptom 1594 1610	Semi-regular BMs
A84	NegationModalityVal T289 negated
T290	PhysicalActivity 1636 1647	very active
T291	PhysicalActivity 1649 1660	working out
T292	Frequency 1661 1670	5x/weekly
R20	Temporal Arg1:T292 Arg2:T291	
T293	RadPathResult 1310 1333	MMR proteins all intact
A85	RadPathResultVal T293 Others
T294	Pathology 1337 1340	IHC
A86	IntentVal T294 diagnosis
R21	ResultOfTest Desc:T293 Test:T294	
T295	Datetime 1158 1168	05/28/2021
R22	HappensAtOnDuring Arg1:T295 Arg2:T264	
T296	Site 1196 1211	pancreatic tail
R23	SiteOf Arg1:T296 Arg2:T270	
A87	NegationModalityVal T268 uncertain_in_present
A88	NegationModalityVal T269 uncertain_in_present
T297	ClinicalCondition 1929 1936	Anxiety
A89	ChronicVal T297 chronic
A90	ContinuityVal T297 stable
T298	ClinicalCondition 1959 1982	Environmental allergies
A91	ChronicVal T298 chronic
A92	ContinuityVal T298 stable
T299	ClinicalCondition 1986 1989	HIV
A93	NegationModalityVal T299 negated
T300	SectionSkip 2003 2243	Medications:   oxyCODONE-acetaminophen (Percocet) 5-325 mg tablet Take 2 tablets by mouth every 6 (six) hours if needed for severe pain for up to 10 days. 30 tablet 0    valACYclovir (Valtrex) 1 gram tablet prn cold sores   Lorazepam PRN
A94	SectionSkipType T300 medications
T301	SectionSkip 2249 2296	Allergies/Contraindications  No Known Allergies
A95	SectionSkipType T301 allergies
A96	ExperiencerVal T68 family
A97	ExperiencerVal T69 family
A98	ExperiencerVal T70 family
T302	MaritalStatus 2516 2523	Married
A99	IsStoppedOrContinuing T302 continuing
T303	PatientCharacteristics 2535 2546	no children
T304	Employment 2588 2593	*****	
A100	IsStoppedOrContinuing T304 stopped
T305	Employment 2600 2611	***** *****
A101	IsStoppedOrContinuing T305 continuing
T306	Tobacco 2646 2659	Former Smoker
A102	IsStoppedOrContinuing T306 stopped
T307	Datetime 2695 2699	1992
T308	ConsumptionQuantity 2675 2679	0.00
R24	ConsumptionQuantityRel Arg1:T308 Arg2:T306	
R25	EndsOnOrAt Arg1:T307 Arg2:T306	
T309	Duration 2726 2730	30.3
R26	Temporal Arg1:T309 Arg2:T306	
T310	Alcohol 2814 2817	Yes
A104	IsStoppedOrContinuing T310 continuing
T311	ConsumptionQuantity 2836 2861	5.0 - 8.0 standard drinks
R27	ConsumptionQuantityRel Arg1:T311 Arg2:T310	
T312	ConsumptionQuantity 2873 2917	5 - 8 Standard drinks or equivalent per week
R28	ConsumptionQuantityRel Arg1:T312 Arg2:T310	
T313	ConsumptionQuantity 2935 2941	5-8/wk	
R29	ConsumptionQuantityRel Arg1:T313 Arg2:T310	
T314	Drugs 2956 2959	Yes
A105	IsStoppedOrContinuing T314 continuing
T315	SectionSkip 2999 3908;3911 4209	Physical Exam:  ECOG PS 0  Blood pressure (!) 172/103, pulse 83, temperature 36.4 C (97.6 F), temperature source Temporal, resp. rate 16, height 172.5 cm (5' 7.91"), weight 82.1 kg (181 lb), SpO2 97 %.  General appearance: No acute distress, conversant, appropriately interactive. Non-toxic, well-appearing.   Eyes: anicteric sclerae, moist conjunctivae; no lid lag.   HEENT: Atraumatic; oropharynx clear with moist mucous membranes and no mucosal ulcerations; normal hard and soft palate  Neck: Full range of motion, supple, no lymphadenopathy  Lungs/respiratory: Clear to auscultation, with normal respiratory effort and no intercostal retractions  Cardiovascular: RRR, normal S1 S2, no murmurs, gallops, or rubs.  Abdomen/GI: Soft, non-tender, nondistended; no masses, ascites, or hepatomegaly. Tympanitic to percussion.  Back: No point spinal tenderness.  Extremities: No peripheral edema or discoloration palpated or visualized.  Skin: Normal temperature, turgor and texture; no rash, ulcers or subcutaneous nodules visualized or palpated.  Neuro: Normal bulk, tone, and strength in upper and lower extremities. Intact gait. No focal sensorimotor deficits.  Psych: Appropriate affect, alert and oriented
A106	SectionSkipType T315 physical_exam
T316	SectionSkip 4621 5841;5844 7127	FINDINGS:    Lines / tubes: None.     Lower Thorax: Normal.      Hepatobiliary:    Liver: Measures 14.9 cm in craniocaudal dimension. Multiple varying sized hypodense lesions   throughout the right and left lobes of the liver are present measuring up to 1.7 x 1.4 cm in   segment March 13 (axial image 19, series 2) and 0.9 x 0.8 cm in segments August 15 (axial image 16,   series 2).    Gallbladder: Normal.    Bile Ducts: Normal.    Hepatic vasculature: Normal.     Spleen: A wedge-shaped hypodense area is noted in the lower part of the spleen most likely   related to an infarct. Spleen is upper limits of normal size measuring 12.6 cm.     Pancreas: A 5 x 4.1 cm cystic lesion with irregular rim enhancement is noted involving the   pancreatic tail and abutting the splenic hilum. No pancreatic duct dilatation is noted.     Adrenals: Normal.     Kidneys/Ureters: Normal.     GI Tract:    GE junction and stomach: Normal.    Small bowel: Normal in diameter    Appendix: Not visualized.    Colon and rectum: Diffuse wall thickening of the descending and sigmoid colon is present.     Peritoneum / Retroperitoneum: Nodular foci of enhancement involving the greater omentum is   present. Small peritoneal free fluid is present. Irregular foci of nodular peritoneal   enhancement are present. Example in the left lateral peritoneal line (axial image 42, series   2).     Diffuse mesenteric edema with interspersed fluid is noted.     Lymph Nodes: Multiple retroperitoneal lymph nodes are present in an example left periaortic   lymph node (axial image 42, series 2) measuring 0.9 x 1.1 cm.     Vessels: Moderate atherosclerotic ossification of aorta.     Pelvis:    Prostate: Normal.    Seminal vesicles: Normal.    Bladder: Normal.     Bones and Soft Tissues: Normal.     IMPRESSION:  1. A lobulated cystic lesion with rim enhancement is noted involving the pancreatic tail   measuring 5 x 4.1 cm in size. This may represent a cystic neoplastic process, necrotic   metastatic disease or sequelae of prior inflammation.   2. Multiple hypodense lesions throughout the liver are present suspicious for   metastatic/neoplastic process.   3. Diffuse omental caking and multiple foci of nodular peritoneal enhancement are noted   representing peritoneal carcinomatosis. Small peritoneal free fluid and diffuse mesenteric   edema is present.   4. Wall thickening of the descending and sigmoid colon may be reactive to peritonitis or   related to colitis.   5. Prominent retroperitoneal lymph nodes are present
A107	SectionSkipType T316 radiology_report
T317	Age 7195 7197	51
T318	ClinicalCondition 7240 7265	pancreatic adenocarcinoma
A108	ChronicVal T318 chronic
A109	ContinuityVal T318 stable
T319	Histology 7251 7265	adenocarcinoma
T320	Metastasis 7229 7239	metastatic
T321	TreatmentType 7483 7499	systemic therapy
A110	NegationModalityVal T321 hypothetical_in_future
A111	TreatmentTypeVal T321 maintenance
A112	TreatmentIntentVal T321 palliative
T322	TreatmentType 7642 7651	treatment
A113	NegationModalityVal T322 hypothetical_in_future
A114	TreatmentTypeVal T322 maintenance
A115	TreatmentIntentVal T322 palliative
T323	TreatmentType 7757 7764	therapy
A116	NegationModalityVal T323 hypothetical_in_future
A117	TreatmentTypeVal T323 maintenance
A118	TreatmentIntentVal T323 palliative
T324	TreatmentType 7895 7916	chemotherapy regimens
A119	NegationModalityVal T324 hypothetical_in_future
A120	TreatmentTypeVal T324 maintenance
A121	TreatmentIntentVal T324 palliative
T325	ClinicalCondition 7947 7964	pancreatic cancer
A122	ChronicVal T325 chronic
T326	Metastasis 7936 7946	metastatic
R30	TumorDesc TumorDetails:T326 Desc:T325	
R31	TumorDesc TumorDetails:T320 Desc:T318	
T327	MedicationRegimen 8127 8205	FOLFIRINOX (biweekly infusional 5-FU, leucovorin, irinotecan, and oxaliplatin)
A123	NegationModalityVal T327 hypothetical_in_future
A124	TreatmentTypeVal T327 maintenance
A125	TreatmentIntentVal T327 palliative
T328	MedicationRegimen 8228 8259	gemcitabine plus nab-paclitaxel
A126	NegationModalityVal T328 hypothetical_in_future
T329	Symptom 8432 8438	nausea
A129	NegationModalityVal T329 hypothetical_in_future
A130	IsPresentOnFirstCancerDiagnosis T329 no
A131	IsCausedByDiagnosedCancer T329 no
A132	ChronicVal T329 non-chronic
T330	Symptom 8439 8447	vomiting
A133	NegationModalityVal T330 hypothetical_in_future
A134	IsPresentOnFirstCancerDiagnosis T330 no
A135	IsCausedByDiagnosedCancer T330 no
A136	ChronicVal T330 non-chronic
A137	NegationModalityVal T173 hypothetical_in_future
A138	IsPresentOnFirstCancerDiagnosis T173 no
A139	IsCausedByDiagnosedCancer T173 no
A140	ChronicVal T173 non-chronic
A141	NegationModalityVal T174 hypothetical_in_future
A142	IsPresentOnFirstCancerDiagnosis T174 no
A143	IsCausedByDiagnosedCancer T174 no
A144	ChronicVal T174 non-chronic
A145	NegationModalityVal T175 hypothetical_in_future
A146	IsPresentOnFirstCancerDiagnosis T175 no
A147	IsCausedByDiagnosedCancer T175 no
A148	ChronicVal T175 non-chronic
A149	NegationModalityVal T176 hypothetical_in_future
A150	IsPresentOnFirstCancerDiagnosis T176 no
A151	IsCausedByDiagnosedCancer T176 no
A152	ChronicVal T176 non-chronic
A153	NegationModalityVal T177 hypothetical_in_future
A154	IsPresentOnFirstCancerDiagnosis T177 no
A155	IsCausedByDiagnosedCancer T177 no
A156	ChronicVal T177 non-chronic
A157	NegationModalityVal T178 hypothetical_in_future
A158	IsPresentOnFirstCancerDiagnosis T178 no
A159	IsCausedByDiagnosedCancer T178 no
A160	ChronicVal T178 non-chronic
A161	NegationModalityVal T179 hypothetical_in_future
A162	IsPresentOnFirstCancerDiagnosis T179 no
A163	IsCausedByDiagnosedCancer T179 no
A164	ChronicVal T179 non-chronic
R32	ConditionOrTreatmentCausesProblem Treatment:T327 Prob:T330	
R33	ConditionOrTreatmentCausesProblem Treatment:T328 Prob:T330	
R34	ConditionOrTreatmentCausesProblem Treatment:T327 Prob:T329	
R35	ConditionOrTreatmentCausesProblem Treatment:T328 Prob:T329	
R36	ConditionOrTreatmentCausesProblem Treatment:T327 Prob:T173	
R37	ConditionOrTreatmentCausesProblem Treatment:T327 Prob:T174	
R38	ConditionOrTreatmentCausesProblem Treatment:T327 Prob:T175	
R39	ConditionOrTreatmentCausesProblem Treatment:T327 Prob:T176	
R40	ConditionOrTreatmentCausesProblem Treatment:T327 Prob:T177	
R41	ConditionOrTreatmentCausesProblem Treatment:T327 Prob:T178	
R42	ConditionOrTreatmentCausesProblem Treatment:T327 Prob:T179	
R43	ConditionOrTreatmentCausesProblem Treatment:T328 Prob:T173	
R44	ConditionOrTreatmentCausesProblem Treatment:T328 Prob:T174	
A127	IsPresentOnFirstCancerDiagnosis T328 no
A128	IsCausedByDiagnosedCancer T328 no
A165	ChronicVal T328 non-chronic
A166	TreatmentTypeVal T328 maintenance
A167	TreatmentIntentVal T328 palliative
R45	ConditionOrTreatmentCausesProblem Treatment:T328 Prob:T175	
R46	ConditionOrTreatmentCausesProblem Treatment:T328 Prob:T176	
R47	ConditionOrTreatmentCausesProblem Treatment:T328 Prob:T177	
R48	ConditionOrTreatmentCausesProblem Treatment:T328 Prob:T178	
R49	ConditionOrTreatmentCausesProblem Treatment:T328 Prob:T179	
T331	MedicationRegimen 8632 8642	FOLFIRINOX
A168	NegationModalityVal T331 hypothetical_in_future
A169	TreatmentTypeVal T331 maintenance
A170	TreatmentIntentVal T331 palliative
T332	ClinicalCondition 8793 8810	pancreatic cancer
A171	ChronicVal T332 chronic
A172	ContinuityVal T332 stable
T333	Metastasis 8782 8792	metastatic
R50	TumorDesc TumorDetails:T333 Desc:T332	
T334	ClinicalTrial 8907 8924	Precision Promise
A173	NegationModalityVal T334 hypothetical_in_future
T335	TreatmentType 9084 9100	SOC chemotherapy
A174	NegationModalityVal T335 hypothetical_in_future
A175	TreatmentTypeVal T335 maintenance
A176	TreatmentIntentVal T335 palliative
T336	MedicationRegimen 9102 9128	gemcitabine/nab-paclitaxel
A177	NegationModalityVal T336 hypothetical_in_future
A178	TreatmentTypeVal T336 maintenance
A179	TreatmentIntentVal T336 palliative
T337	MedicationRegimen 9132 9142	FOLFIRINOX
A180	NegationModalityVal T337 hypothetical_in_future
A181	TreatmentTypeVal T337 maintenance
A182	TreatmentIntentVal T337 palliative
T338	MedicationName 9244 9255	gemcitabine
A183	NegationModalityVal T338 hypothetical_in_future
A184	TreatmentTypeVal T338 maintenance
A185	TreatmentIntentVal T338 palliative
A186	TreatmentCategory T338 AntiNeoPlastics
A187	NegationModalityVal T193 hypothetical_in_future
A188	TreatmentTypeVal T193 maintenance
A189	TreatmentIntentVal T193 palliative
A190	TreatmentCategory T193 AntiNeoPlastics
A191	NegationModalityVal T194 hypothetical_in_future
A192	TreatmentTypeVal T194 maintenance
A193	TreatmentIntentVal T194 palliative
A194	TreatmentCategory T194 AntiNeoPlastics
T339	ProcedureName 9386 9415	fresh tumor tissue collection
A195	NegationModalityVal T339 hypothetical_in_future
A196	TreatmentTypeVal T339 others
A197	TreatmentIntentVal T339 palliative
A198	TreatmentCategory T339 Others
R51	InclusionCriteriaFor Arg1:T339 Arg2:T334	
T340	ClinicalTrial 9453 9474	REVOLUTION (PICI0044)
T341	TreatmentType 9627 9639	chemotherapy
A199	NegationModalityVal T341 hypothetical_in_future
A200	TreatmentTypeVal T341 maintenance
A201	TreatmentIntentVal T341 palliative
T342	TreatmentType 9640 9653	immunotherapy
A202	NegationModalityVal T342 hypothetical_in_future
A203	TreatmentTypeVal T342 maintenance
A204	TreatmentIntentVal T342 palliative
T343	MedicationName 9753 9764	gemcitabine
A205	NegationModalityVal T343 hypothetical_in_future
A206	TreatmentTypeVal T343 maintenance
A207	TreatmentIntentVal T343 palliative
A208	TreatmentCategory T343 AntiNeoPlastics
A209	NegationModalityVal T203 hypothetical_in_future
A210	TreatmentTypeVal T203 maintenance
A211	TreatmentIntentVal T203 palliative
A212	TreatmentCategory T203 AntiNeoPlastics
A213	NegationModalityVal T204 hypothetical_in_future
A214	TreatmentTypeVal T204 maintenance
A215	TreatmentIntentVal T204 palliative
A216	TreatmentCategory T204 AntiNeoPlastics
T344	MedicationName 9865 9875	ipilimumab
A217	NegationModalityVal T344 hypothetical_in_future
A218	TreatmentTypeVal T344 maintenance
A219	TreatmentIntentVal T344 palliative
A220	TreatmentCategory T344 AntiNeoPlastics
T345	ProcedureName 9954 9977	archived tumor material
A221	NegationModalityVal T345 hypothetical_in_future
A222	TreatmentTypeVal T345 others
A223	TreatmentIntentVal T345 palliative
A224	TreatmentCategory T345 Others
T346	ProcedureName 9983 10009	fresh pre-treatment biopsy
A225	NegationModalityVal T346 hypothetical_in_future
A226	TreatmentTypeVal T346 others
A227	TreatmentIntentVal T346 palliative
A228	TreatmentCategory T346 Others
R52	InclusionCriteriaFor Arg1:T340 Arg2:T345	
R53	InclusionCriteriaFor Arg1:T340 Arg2:T346	
T347	GenomicTest 10110 10131	somatic tumor testing
A229	NegationModalityVal T347 hypothetical_in_future
A230	IntentVal T347 diagnosis
A231	GenomicTestType T347 Somatic
T348	ProcedureName 10149 10163	tumor specimen
A232	NegationModalityVal T348 hypothetical_in_future
T349	GenomicTestResult 10233 10253	actionable mutations
A233	NegationModalityVal T349 hypothetical_in_future
A234	GenomicTestType T349 Somatic
R54	ResultOfTest Desc:T349 Test:T347	
T350	GenomicTestResult 10263 10282	genetic alterations
A235	NegationModalityVal T350 hypothetical_in_future
A236	GenomicTestType T350 Somatic
R55	ResultOfTest Desc:T350 Test:T347	
T351	TreatmentType 10306 10323	treatment options
A237	NegationModalityVal T351 hypothetical_in_future
A238	GenomicTestType T351 Somatic
A239	TreatmentTypeVal T351 maintenance
A240	TreatmentIntentVal T351 palliative
R56	InclusionCriteriaFor Arg1:T349 Arg2:T351	
R57	InclusionCriteriaFor Arg1:T350 Arg2:T351	
T352	TreatmentType 10338 10361	already-approved agents
A241	NegationModalityVal T352 hypothetical_in_future
A242	TreatmentTypeVal T352 maintenance
A243	TreatmentIntentVal T352 palliative
R58	InclusionCriteriaFor Arg1:T349 Arg2:T352	
R59	InclusionCriteriaFor Arg1:T350 Arg2:T352	
T353	GenomicTest 10681 10697	germline testing
A244	NegationModalityVal T353 hypothetical_in_future
A245	IntentVal T353 screening
A246	GenomicTestType T353 Germline
T354	ClinicalCondition 10802 10819	pancreatic cancer
T355	MedicationName 11067 11073	opioid
A247	NegationModalityVal T355 negated
A248	TreatmentCategory T355 Supportive
T356	ClinicalTrial 11194 11216	non-therapeutic trials
A249	NegationModalityVal T356 hypothetical_in_future
T357	DiagnosticLabTest 11267 11272;11290 11296	blood assays
A250	IntentVal T357 others
T358	DiagnosticLabTest 11255 11262	imaging
A251	IntentVal T358 others
T359	DiagnosticLabTest 11278 11283	stool
A252	IntentVal T359 others
T360	GenomicTest 11302 11307	ctDNA
A253	IntentVal T360 others
A254	GenomicTestType T360 Somatic
T361	GenomicTest 11312 11322	microbiome
A255	GenomicTestType T361 GeneExpression
A256	NegationModalityVal T360 hypothetical_in_future
A257	NegationModalityVal T361 hypothetical_in_future
A258	NegationModalityVal T357 hypothetical_in_future
A259	NegationModalityVal T359 hypothetical_in_future
A260	NegationModalityVal T358 hypothetical_in_future
T362	ClinicalTrial 11550 11560	REVOLUTION
A261	NegationModalityVal T362 planned_in_future
R60	TestOrProcedureReveals Test:T263 Desc:T267	
R61	HappensAtOnDuring Arg1:T262 Arg2:T263	
R62	HappensAtOnDuring Arg1:T247 Arg2:T249	
R5	HappensAtOnDuring Arg1:T247 Arg2:T250	
R63	HappensAtOnDuring Arg1:T258 Arg2:T259	
R64	TestOrProcedureReveals Test:T264 Desc:T271	
R65	SizeOf Arg1:T267 Arg2:T265	
R66	SizeOf Arg1:T271 Arg2:T270	
T363	hpi_start 0 2	Mr
T364	hpi_end 1833 1840	anxiety
T365	ap_start 7135 7145	Impression
T366	ap_end 11971 11982	toxicities.
